NCT07403916Active, not recruiting
Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer
Source: ClinicalTrials.gov · Last updated 11 Feb 2026
Brief summary (registry, in English)
Next-generation sequencing (NGS) and biomarkers play a key role in the diagnosis and personalized therapy of gastric cancer. These technologies provide a deep understanding of the molecular basis of the disease. NGS allows simultaneous analysis of multiple genes, identifying mutations and changes in their expression. In case of stomach cancer, this makes it possible to identify specific mutations to determine prognosis and treatment choice, study the genomic profiles of patients to find targets for targeted and immunotherapy. The use of NGS and biomarkers allows the development of individualized treatment regimens, increasing effectiveness and reducing side effects. Biomarker analysis also helps to track the progression of the disease and identify patients at high risk of relapse. The study of molecular genetic markers in tumor tissues, as well as the influence of genetic and age-related factors, is an important scientific and clinical task. Solving this problem will create a personalized approach to patient management. This work examines the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on the analysis of surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations in various age groups.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 90 (actual)
- First submitted
- 4 Feb 2026
- Start date
- 10 Jan 2020
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- P. Herzen Moscow Oncology Research Institute
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07403916
What you commit to
- Study type: Observational
- Participants enrolled: 90
- From 10 Jan 2020 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnostic and palliative surgery
Other
- The presence of metastases in distant organs at the time of diagnosis
- Primary-multiple tumors
- Incomplete clinical data
- Pregnancy
Who the study is looking for
- Patients with histologically confirmed diagnosis of gastric cancer
- The resectable stage of the disease (I-III)
- Availability of complete clinical data, including age, gender, stage of the disease, concomitant diseases, treatment tactics and outcomes
- Indicated radical surgical intervention both at the first stage and after neoadjuvant chemotherapy
- Localization of the tumor: Type II-III cardioesophageal junction according to Siewert, upper, middle and lower third of the body, angle of the stomach or antrum (U,M,L-level according to the Japanese classification)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| P.Herzen Moscow Oncological Research Institute Coordinator of this site? Confirm its status | Moscow | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.